Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2026)
Pliant Therapeutics (PLRX) reported Income from Continuing Operations of 20040000.0 for Q1 2026, up 64.32% year-over-year from 12195711.87 in Q1 2025, and up 7.86% quarter-over-quarter from 21749000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has 8 years of Income from Continuing Operations data on file, last reported at 20040000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 20040000.0, up 64.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 111390000.0 (up 49.26% YoY), and the FY2025 annual result was 147516000.0, up 29.86% from the prior year.
- Income from Continuing Operations climbed to 20040000.0 in Q1 2026 per PLRX's latest filing, from 21749000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 20040000.0 in Q1 2026 and troughed at 57763000.0 in Q3 2024.
- A 5-year average of 38971588.24 and a median of 41109000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations plunged 42.92% in 2022, then surged 64.32% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 35060000.0 in 2022, then fell by 17.25% to 41109000.0 in 2023, then decreased by 20.98% to 49732000.0 in 2024, then jumped by 56.27% to 21749000.0 in 2025, then gained by 7.86% to 20040000.0 in 2026.
- Business Quant data shows PLRX's Income from Continuing Operations at 20040000.0 in Q1 2026, 21749000.0 in Q4 2025, and 26301000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Pliant Therapeutics | 74.16 Mn | 74.16 Mn | - | -20.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.04 Mn |
| Dec 31, 2025 | -21.75 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -43.30 Mn |
| Mar 31, 2025 | -56.17 Mn |
| Dec 31, 2024 | -49.73 Mn |
| Sep 30, 2024 | -57.76 Mn |
| Jun 30, 2024 | -55.85 Mn |
| Mar 31, 2024 | -46.96 Mn |
| Dec 31, 2023 | -41.11 Mn |
| Sep 30, 2023 | -41.49 Mn |
| Jun 30, 2023 | -41.19 Mn |
| Mar 31, 2023 | -37.55 Mn |
| Dec 31, 2022 | -35.06 Mn |
| Sep 30, 2022 | -30.62 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | -24.53 Mn |
| Sep 30, 2021 | -27.05 Mn |
| Jun 30, 2021 | -22.83 Mn |